Over 40 weeks, people on Mounjaro lost 7.6 kg, 9.3 kg or 11.2 kg, depending on the dose, and people on semaglutide 1 mg, the drug in Ozempic, lost 5.7 kg. HbA1c fell 2.0 to 2.3 points on Mounjaro and 1.9 points on semaglutide. Stomach side effects were about as common on both.
The trial used Ozempic's 1 mg dose, not its current top dose of 2 mg, and Ozempic has heart and kidney indications that Mounjaro's label does not. This page puts the trial into your own weight and sets the two labels side by side: results, side effects, dose schedules and missed-dose rules.
What did the head-to-head trial find?
The trial is called SURPASS-2. It enrolled 1,879 adults with type 2 diabetes that was not controlled on metformin and assigned them to Mounjaro 5 mg, 10 mg or 15 mg, or to semaglutide 1 mg, once a week for 40 weeks. At the start their average HbA1c was 8.3% and their average weight about 94 kg.1,3
All four groups took metformin as well. Semaglutide 1 mg is a dose of Ozempic; the 2 mg dose was not part of this trial.
On blood sugar the gap was small. HbA1c fell 1.9 points on semaglutide and 2.0, 2.2 and 2.3 points on the three Mounjaro doses, and 79% against 82% to 86% finished below 7%. The published analysis found all three Mounjaro doses superior to semaglutide on HbA1c.1,3
Few people in any group needed an extra diabetes medicine during the trial: rescue medication was started by 3% on semaglutide and by 2%, 1% and 1% on Mounjaro 5, 10 and 15 mg.1
On weight the gap was wide and grew with the dose: 1.9 kg more than semaglutide on 5 mg, 3.6 kg more on 10 mg and 5.5 kg more on 15 mg.3
What would that look like at my weight?
The trial reports weight in kilograms for people who averaged 94 kg. To carry it over to another body weight, the calculator turns each group's average loss into a share of that group's average starting weight and applies the share to yours.
Log your weight each week and see your own line next to these averages.
Open the appShares used: 6.1% for semaglutide 1 mg and 8.2%, 9.8% and 11.9% for Mounjaro 5, 10 and 15 mg, our arithmetic from the label's averages. These are averages in people with type 2 diabetes over 40 weeks, not a forecast for one person.
| Group | Average start kg | Average loss kg | As a share |
|---|---|---|---|
| Semaglutide 1 mg | 93.7 | 5.7 | 6.1% |
| Mounjaro 5 mg | 92.5 | 7.6 | 8.2% |
| Mounjaro 10 mg | 94.8 | 9.3 | 9.8% |
| Mounjaro 15 mg | 93.8 | 11.2 | 11.9% |
Mounjaro prescribing information, Table 5; the last column is our division.1
What did each drug do in its own trials?
Each label also has a trial of the drug on its own against placebo, in adults whose diabetes was not controlled by diet and exercise. They are separate trials of different length, so the rows below show what each drug did, not which one is better.1,2
| Drug alone, against placebo | HbA1c | HbA1c under 7% | Weight kg |
|---|---|---|---|
| Ozempic 0.5 mg, 30 weeks | โ1.4 | 73% | โ3.8 |
| Ozempic 1 mg, 30 weeks | โ1.6 | 70% | โ4.7 |
| Placebo in that trial | โ0.1 | 28% | โ1.2 |
| Mounjaro 5 mg, 40 weeks | โ1.8 | 82% | โ6.3 |
| Mounjaro 10 mg, 40 weeks | โ1.7 | 85% | โ7.0 |
| Mounjaro 15 mg, 40 weeks | โ1.7 | 78% | โ7.8 |
| Placebo in that trial | โ0.1 | 23% | โ1.0 |
Ozempic prescribing information, Table 3; Mounjaro prescribing information, Table 4.1,2
Both labels also report trials against insulin, and there the two drugs behaved alike in one respect: people on insulin gained weight and people on either drug lost it. Against insulin glargine, weight fell 3.2 kg and 4.7 kg on Ozempic 0.5 mg and 1 mg over 30 weeks while it rose 0.9 kg on insulin. Against the same insulin over 52 weeks, weight fell 6.4, 8.9 and 10.6 kg on Mounjaro 5, 10 and 15 mg while it rose 1.7 kg on insulin.1,2
How did each do against other diabetes drugs?
The labels report several trials against established treatments. In each, the drug lowered weight while the comparison drug did less or raised it.1,2
| Trial | Weight change on the drug | Comparison kg |
|---|---|---|
| Ozempic 0.5 and 1 mg against sitagliptin, 56 weeks | โ4.2 kg and โ5.5 kg | โ1.7 |
| Ozempic 1 mg against exenatide ER, 56 weeks | โ4.8 kg | โ2.0 |
| Ozempic 0.5 and 1 mg against insulin glargine, 30 weeks | โ3.2 kg and โ4.7 kg | +0.9 |
| Mounjaro 5, 10, 15 mg against insulin degludec, 52 weeks | โ7.0, โ9.6 and โ11.3 kg | +1.9 |
| Mounjaro 5, 10, 15 mg against insulin glargine, 52 weeks | โ6.4, โ8.9 and โ10.6 kg | +1.7 |
Section 14 of each label. Different trials, lengths and background medicines.1,2
Mounjaro's results in these trials grow with the dose, by about 2 kg for each step from 5 mg to 10 mg to 15 mg. On HbA1c the steps were smaller: against insulin degludec it fell 1.9, 2.0 and 2.1 points on the three doses.1
What does the trial leave open?
Four things limit how far the result can be stretched.
The Ozempic dose. The comparison used 1 mg. Ozempic now goes to 2 mg, and in its own trial of 961 people, 2 mg lowered HbA1c by 2.1 points against 1.9 on 1 mg and weight by 6.4 kg against 5.6 kg.2 Those numbers come from a different trial with a different starting point, so they cannot simply be set next to the Mounjaro arms.
The design. Patients and doctors knew which drug they were getting; only the Mounjaro dose was hidden. The trial was paid for by Lilly, the maker of Mounjaro.3
The people. Everyone had type 2 diabetes and took metformin, so the result does not carry over to people without diabetes.
The length. The trial lasted 40 weeks and does not show what happens after that.
Which has more side effects?
In the head-to-head trial, about the same. The most common adverse events in every group were in the stomach and gut, and most were mild to moderate.3
The published report gives one figure for semaglutide and a range across the three Mounjaro doses.
Nausea was reported by 18% on semaglutide and by 17% to 22% across the Mounjaro doses, diarrhea by 12% and 13% to 16%, vomiting by 8% and 6% to 10%. Serious adverse events of any kind were more frequent on Mounjaro: 5% to 7%, against 3% on semaglutide.3
Low blood sugar was rare on both. A reading below 54 mg/dL was reported in 0.4% of people on semaglutide and in 0.6%, 0.2% and 1.7% on Mounjaro 5, 10 and 15 mg.3
Each label's own table shows the same pattern within a drug: stomach reactions rise with the dose. On Ozempic, nausea went from 15.8% on 0.5 mg to 20.3% on 1 mg; on Mounjaro, from 12% on 5 mg to 18% on 15 mg. Those tables come from different trials and should not be compared across drugs.1,2
What else do the safety tables show?
These figures come from each drug's own placebo-controlled trials. They describe each drug and are not a head-to-head comparison.1,2
| Ozempic | Mounjaro | |
|---|---|---|
| Stopped because of stomach or gut reactions | 3.1% on 0.5 mg, 3.8% on 1 mg; placebo 0.4% | 3.0% on 5 mg, 5.4% on 10 mg, 6.6% on 15 mg; placebo 0.4% |
| Heart rate | Up 2 to 3 beats a minute | Up 2 to 4 beats a minute |
| Injection site reactions | 0.2% | 3.2%; placebo 0.4% |
| Gallbladder | Gallstones in 1.5% on 0.5 mg and 0.4% on 1 mg; none on placebo | Acute gallbladder disease in 0.6%; none on placebo |
| Pancreatic enzymes | Amylase up 13%, lipase up 22% | Amylase up 33% to 38%, lipase up 31% to 42% |
Low blood sugar depends more on the other medicines than on which of the two is used. Alone, neither caused severe episodes in its placebo-controlled trial. Added to basal insulin, a reading of 70 mg/dL or below with symptoms was reported by 16.7% and 29.8% on Ozempic 0.5 mg and 1 mg, against 15.2% on placebo; a reading below 54 mg/dL was reported by 16%, 19% and 14% on Mounjaro 5, 10 and 15 mg, against 13% on placebo. The two labels use different thresholds, so these rows cannot be compared with each other either.1,2
What differs for birth control, pregnancy and age?
Three differences in the labels matter to particular groups.1,2
Birth control pills. Mounjaro's label advises people on oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Ozempic's label says that in its clinical pharmacology trials semaglutide did not affect the absorption of oral medicines to a clinically relevant degree, and gives no such instruction.
Pregnancy. Ozempic's label says to stop the drug at least 2 months before a planned pregnancy because it takes that long to leave the body. Mounjaro's label says it should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Age. Mounjaro is approved from age 10, with a maximum of 10 mg. Ozempic's safety and efficacy have not been established in pediatric patients. For older adults, kidney impairment and liver impairment, neither label asks for a different dose.
How do the pens differ?
An Ozempic pen holds several weekly doses, and there are three of them: one pen for 0.25 mg and 0.5 mg, one for 1 mg, one for 2 mg. The current label adds single-dose prefilled syringes of 0.25 mg, 0.5 mg and 1 mg.2
Mounjaro comes in four forms, each in all six strengths: a single-dose pen, a single-dose vial, a KwikPen with four weekly doses and a multi-dose vial with four weekly doses.1
| Storage | Ozempic pen | Mounjaro |
|---|---|---|
| Before first use | Refrigerator | Refrigerator; a single-dose pen or vial may be out, up to 86ยฐF, for a total of 21 days |
| After first use | 56 days, at room temperature or refrigerated | KwikPen or multi-dose vial: discard 30 days after first use or after four weekly doses |
Which has evidence for the heart and kidneys?
Ozempic, by indication. Its label includes two uses beyond blood sugar: reducing major cardiovascular events in adults with type 2 diabetes and cardiovascular disease, and reducing kidney function decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.2
Ozempic outcome trials, against placebo
Mounjaro's label has one use, blood sugar control.1 Its cardiovascular trial was published in 2025. It compared Mounjaro with dulaglutide, a weekly drug already shown to reduce cardiovascular events, in 13,165 people with type 2 diabetes and cardiovascular disease. A cardiovascular death, heart attack or stroke occurred in 12.2% on Mounjaro and 13.1% on dulaglutide. That met the test of being no worse and did not meet the test of being better.4
So the two drugs have been tested against different yardsticks: Ozempic against placebo, Mounjaro against a drug that already helps. Neither trial compared Ozempic with Mounjaro.
Which warnings do the two labels share?
Most of them. Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.1,2
Both also list the same set of warnings: pancreatitis, low blood sugar when used with insulin or a sulfonylurea, acute kidney injury from dehydration, severe stomach and gut reactions, worsening of diabetic retinopathy, gallbladder disease, serious allergic reactions, and aspiration of stomach contents during general anesthesia or deep sedation.1,2 These sections read much the same in both labels.
How long does each stay in the body?
Ozempic longer. Semaglutide has a half-life of about one week, reaches a steady level after 4 to 5 weeks of weekly doses, and stays in the circulation for about 5 weeks after the last dose. Tirzepatide has a half-life of about 5 days and reaches a steady level after 4 weeks.1,2 In our model, about 2% of the usual weekly peak of tirzepatide is left four weeks after the last dose.
The longer half-life goes with two practical differences on this page: the wider window for a missed Ozempic dose, and the label's advice to stop Ozempic at least 2 months before a planned pregnancy.
Do people stay on one longer than the other?
There is one comparison, and it is for the weight-loss versions of the two molecules in people without diabetes. Among health plan members who started in the first half of 2024, 64.8% of those on tirzepatide and 58.6% of those on semaglutide were still on treatment a year later.7 The groups were not randomised, the authors work for the company that paid for the analysis, and the figures do not describe Ozempic or Mounjaro users with diabetes.
How do the two labels differ?
| Ozempic | Mounjaro | |
|---|---|---|
| Drug | Semaglutide, a GLP-1 receptor agonist | Tirzepatide, a GIP and GLP-1 receptor agonist |
| Approved for | Blood sugar control, cardiovascular risk and kidney disease in adults with type 2 diabetes | Blood sugar control in type 2 diabetes, from age 10 |
| Doses | 0.25, 0.5, 1, 2 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Earliest top dose | Week 13 | Week 21 |
| Half-life | About 1 week | About 5 days |
| Missed dose | Take within 5 days | Take within 4 days |
| Changing the day | At least 2 days between doses | At least 3 days between doses |
| Children | Not established | From age 10, up to 10 mg |
Current prescribing information for each product.1,2
Neither is approved for weight loss. The same molecules are sold for that purpose under other names and labels: Wegovy for semaglutide, at higher doses, and Zepbound for tirzepatide. The Wegovy vs Zepbound page covers the trial that compared those two.
How do the dose schedules compare?
Both start with four weeks on a low starting dose, and both allow a step up every four weeks at the earliest. Ozempic has three steps and Mounjaro five, so Mounjaro takes longer to reach its top.1,2
Log each shot and the app keeps the dates for you.
Open the appThe numbers along the bottom are weeks of treatment. These are the earliest dates each label allows. Steps are taken only if more blood sugar control is needed, and the prescriber decides each one.
The pages on the Ozempic dosing schedule and the Mounjaro dosing schedule go through each step, with trial results and side effects by dose.
What if a dose is late?
Ozempic gives a day more. Its label says to take a missed dose within 5 days; Mounjaro's says within 4 days, or 96 hours. After that, both say to skip it and take the next dose on the usual day.1,2
Each curve is a share of that drug's own weekly peak, from a model built on the label half-lives. The curves compare how fast each drug fades, not how strong it is.
The different windows follow from how fast each drug leaves. Semaglutide's half-life is about a week and tirzepatide's about 5 days, so a week after a dose semaglutide is at about 62% of its peak in our model and tirzepatide at about 44%.1,2 The page on the week between shots shows both curves day by day.
What do they cost?
With commercial insurance that covers the drug, each manufacturer's savings offer brings either one to as little as $25. Without coverage the two companies do different things: Novo Nordisk publishes a self-pay price for Ozempic, and Lilly offers a reduced price on Mounjaro to people whose commercial plan does not cover it.5,6
Log each fill and what it cost, and the app adds up your year.
Open the appThirteen four-week fills make a year. Covered: the floor of each savings offer; Novo Nordisk's offer takes off up to $100 a month and Lilly's up to $150, so a plan that charges more leaves more to pay. Not covered: Ozempic at NovoCare's self-pay prices with the new-patient offer; Mounjaro at $499 a fill, which needs commercial insurance that does not cover it. Lilly's card and Novo Nordisk's new-patient offer run through December 31, 2026.
| Ozempic | Mounjaro | |
|---|---|---|
| With commercial coverage | As little as $25; up to $100 off a month | As little as $25 for a 1-, 2- or 3-month fill; up to $150 off a month and $1,950 a year |
| Without coverage | $199 a month for the first two fills for new patients, then $349 for 0.25 to 1 mg and $499 for 2 mg | As low as $499 a fill for people whose commercial plan does not cover it |
| List price | $1,027.51 a pen | Not stated on the savings page |
| Medicare Part D | Savings offer excludes government beneficiaries | About 8 in 10 patients pay $0 to $50 for 28 days; the rest average about $262 |
Ozempic and NovoCare pages and Lilly's Mounjaro savings page, read November 20, 2026. Lilly's Medicare figures are IQVIA data for October 2024 to September 2025.5,6
Can I switch from one to the other?
Neither label gives a procedure for switching between the two drugs. Both start every patient at the lowest dose, 0.25 mg for Ozempic and 2.5 mg for Mounjaro, to reduce stomach and gut side effects.1,2 Which dose to begin the new drug on after the old one is a decision for the prescriber. The page on switching from Wegovy to Zepbound covers the same two molecules and what is known about the change.
Short answers to common questions
Is Mounjaro stronger than Ozempic?
In the one direct trial, all three Mounjaro doses lowered HbA1c and weight more than semaglutide 1 mg. The trial did not include Ozempic's 2 mg dose.
Which is better for weight loss?
In the trial, people lost 5.7 kg on semaglutide 1 mg and 7.6 to 11.2 kg on Mounjaro over 40 weeks. Neither product is approved for weight loss; Wegovy and Zepbound are the versions with that indication.
Which has fewer side effects?
In the same trial, nausea, diarrhea and vomiting were about as common on both. Serious adverse events were reported in 3% on semaglutide and 5% to 7% on Mounjaro.
Which protects the heart?
Ozempic is approved to reduce major cardiovascular events in adults with type 2 diabetes and cardiovascular disease. Mounjaro was no worse than dulaglutide in its cardiovascular trial and has no heart indication in its label.
Are Ozempic and Mounjaro the same drug?
No. Ozempic is semaglutide, which acts on the GLP-1 receptor. Mounjaro is tirzepatide, which acts on the GIP and GLP-1 receptors.
Which reaches its full dose sooner?
Ozempic: week 13 at the earliest for 2 mg, against week 21 for 15 mg of Mounjaro.
What if I miss a dose?
Ozempic can be taken up to 5 days late and Mounjaro up to 4 days late. After that the missed dose is skipped.
Which is cheaper?
With commercial coverage both can cost as little as $25 a fill under the manufacturers' offers. Without coverage, Ozempic is $349 a month at NovoCare for doses up to 1 mg and $499 for 2 mg, and Lilly's reduced price for Mounjaro is $499 a fill for people whose commercial plan does not cover it.
Do I need backup birth control on either?
Mounjaro's label advises a non-oral or barrier method for 4 weeks after starting and after each dose increase for people who take the pill. Ozempic's label has no such instruction.
Can children take either one?
Mounjaro is approved from age 10 for type 2 diabetes, up to 10 mg a week. In its pediatric trial, HbA1c fell 1.9 points on 5 mg and 2.2 points on 10 mg over 30 weeks, against 0.2 on placebo. Ozempic's safety and efficacy have not been established in pediatric patients.
Do they carry the same warnings?
Largely. Both have a boxed warning about thyroid C-cell tumors and the same contraindications, and both list pancreatitis, gallbladder disease, kidney injury from dehydration and severe stomach reactions.
Which one leaves the body faster?
Mounjaro. Its half-life is about 5 days, against about a week for Ozempic, which the label says stays in the circulation for about 5 weeks after the last dose.
How the calculators work
The weight calculator divides each group's average weight loss in SURPASS-2 by that group's average starting weight, which gives 6.1%, 8.2%, 9.8% and 11.9%, and multiplies your weight by those shares. The label reports the result in kilograms, so this step is ours.
The schedule chart places each label's steps at 4-week intervals from the date you enter. The late-dose curves come from our level model: one compartment, a half-life of 7 days and a peak at 2 days for semaglutide, 5 days and 24 hours for tirzepatide, after a long run of weekly doses.
Side effect figures are the ones published for the trial: a single figure for semaglutide and the lowest and highest of the three Mounjaro dose groups.
Sources
- MOUNJARO (tirzepatide) injection prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 1, 2.1, 6.1, 12.1, 14.3 (Table 5). accessdata.fda.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 2.1, 2.2, 6.1, 8.4, 12.3 and 14. accessdata.fda.gov
- Frรญas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515. doi:10.1056/NEJMoa2107519
- Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med 2025;393:2409-2420. doi:10.1056/NEJMoa2505928
- Novo Nordisk. Ozempic cost and insurance coverage, and NovoCare: explaining list price. Read November 20, 2026. ozempic.com
- Eli Lilly and Company. Mounjaro savings and resources: savings card terms and Medicare Part D costs. Read November 20, 2026. mounjaro.lilly.com
- Marshall LZ, Gleason PP, Friedlander N, Farley J, Urick BY. Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists. J Manag Care Spec Pharm 2026;32:281-291. doi:10.18553/jmcp.2026.32.3.281
Related analyses
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
Ozempic vs Zepbound: two drugs, two labels, and the trials that compared them
Wegovy vs Mounjaro: two drugs, two labels, and the trials that compared them
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Log your doses and weight and see your own line next to the trial's.
Open Dose Insider